Immunity, Inflammation and Disease最新文献

{"title":"Correction to “The potential link between Covid-19 and multiple myeloma: A new saga”","authors":"","doi":"10.1002/iid3.1283","DOIUrl":"https://doi.org/10.1002/iid3.1283","url":null,"abstract":"<p>Al-Kuraishy HM, Al-Gareeb AI, Mohammed AA, Alexiou A, Papadakis M, Batiha G-S. The potential link between Covid-19 and multiple myeloma: a new saga. <i>Immun Inflamm Dis</i>. 2022;10:e701. doi:10.1002/iid3.701</p><p>In the 2. MM Section, the sentence “MM is more common in men around the age of 60 years, with a prevalence of 0.7%. Without treatment, the median survival of patients with MM is approximately 7 months. Treatment survival is 4−5 years, and 5-year survival is 54%.¹⁴” is incorrect. The sentence should have read: “Multiple myeloma occurs more frequently in men compared to women, affecting an estimated 230,000 individuals globally over a 5-year period. Typically, patients are diagnosed between the ages of 66 and 70. However, about 37% of patients are under 65 years old. Advances in treatments have progressively improved the 5- and 10-year survival rates, allowing those with multiple myeloma to live longer.^14,139,140,” where reference 139 is Zhou L, Yu Q, Wei G, et al. Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. <i>BMC Cancer</i>. 2021;21:606. https://doi.org/10.1186/s12885-021-08280-y and reference 140 is Ludwig H, Novis Durie S, Meckl A, Hinke A, Durie B. Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment. <i>Oncologist</i>. 2020;25(9):e1406-e1413. https://doi.org/10.1634/theoncologist.2020-0141.</p><p>We apologize for this error.</p>","PeriodicalId":13289,"journal":{"name":"Immunity, Inflammation and Disease","volume":"13 6","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iid3.1283","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144323562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CAR-NK, a Splendid Strategy for Cancer, Especially for Gynecologic Tumor","authors":"Yisen Cao,&nbsp;Liying Wang,&nbsp;Liang Wang","doi":"10.1002/iid3.70210","DOIUrl":"https://doi.org/10.1002/iid3.70210","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>NK cells are a class of innate lymphocytes capable of nonspecifically killing tumor cells without MHC restriction or prior sensitization. Recent advancements in biotechnology, particularly the development of chimeric antigen receptors (CAR) and related technologies, have enabled targeted tumor cell elimination. CAR endows NK cells with enhanced functionality, with the extracellular domains typically consisting of single-chain variable fragments (scFv) for targeting specific antigens. CAR-NK cells have shown excellent results in several preclinical studies and clinical trials for hematologic malignancies. However, their clinical application in the treatment of solid tumors is still insufficient. Current treatments for gynecological cancers primarily involve surgery, chemotherapy, and radiotherapy, all of which often present substantial side effects and variable efficacy. While CAR-T cell therapy has shown effectiveness in certain gynecological tumors, its clinical application is hindered by severe side effects, such as Cytokine Release Syndrome (CRS) and Graft-Versus-Host Disease (GVHD). CAR-NK cell therapy offers improved safety profiles in clinical applications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This review aims to systematically evaluate recent methodological innovations in CAR-NK engineering and their translational potential in tumor-targeted treatment, providing valuable insights for clinical trials and studies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Electronic databases, including PubMed and Web of Science were searched for relevant literature. Keywords are as follows: CAR-NK cell; Chimeric antigen receptor; Solid tumor; cell therapy; gynecological cancers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>CAR-NK engineering has innovations such as multi-targeted CAR design, gene editing for enhanced persistence, and “off-the-shelf” CAR-NK cells compared to CAR-T cells.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>CAR-NK cell therapy combines safety and anti-tumor efficacy, particularly for gynecological cancers.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13289,"journal":{"name":"Immunity, Inflammation and Disease","volume":"13 6","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iid3.70210","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144300395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Misdiagnosis of ANCA-Associated Vasculitis in Patients With Cocaine/Levamisole–Associated Autoimmune Syndrome and Cocaine-Induced Midline Destructive Lesions: A Case Series","authors":"Kehinde Sunmboye,&nbsp;Ameen Jubber,&nbsp;Maumer Durrani,&nbsp;Jeremy Royle,&nbsp;Shireen Shaffu","doi":"10.1002/iid3.70215","DOIUrl":"https://doi.org/10.1002/iid3.70215","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Cocaine/Levamisole-Associated Autoimmune Syndrome (CLAAS) encompasses a spectrum of autoimmune and vasculitic phenomena, which includes Cocaine-Induced Midline Destructive Lesions (CIMDL), which can mimic ANCA-associated vasculitis (AAV) due to overlapping clinical features and the potential for ANCA positivity. These similarities can lead to misdiagnosis and inappropriate immunosuppressive therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study highlights a case series of seven patients (from 2015 to 2024) with CLAAS with its subset of CIMDL, initially misdiagnosed as active AAV, in patients who were referred to various clinicians in the Rheumatology unit of a Tertiary Hospital in the United Kingdom.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>All patients presented with nasal symptoms, and they all exhibited additional systemic manifestations consistent with CLAAS. Five were ANCA-positive at initial evaluation, leading to the initiation of immunosuppressive therapy; however, symptoms persisted. The diagnoses were then revised to CIMDL in all cases within the broader context of CLAAS following the identification of cocaine use after further patient inquiry and urine toxicology for drug of abuse (DOA) screening found cocaine metabolites.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>A comprehensive drug history and urine toxicology screening are crucial in patients with suspected AAV, as ANCA positivity can occur in CLAAS as well as its subset of CIMDL, complicating the diagnosis. Differentiating between AAV and CIMDL related to CLAAS is essential to avoid unnecessary immunosuppression.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13289,"journal":{"name":"Immunity, Inflammation and Disease","volume":"13 6","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iid3.70215","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144300396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of Prognostic Nutritional Index and Systemic Immune-Inflammation Index Inpatients With Sudden Sensorineural Hearing Loss: A Large Prospective Cohort Study","authors":"Xu Zhang,&nbsp;Junyi Wu,&nbsp;Wentao Zhang,&nbsp;Maohua Wang,&nbsp;Bing Guan,&nbsp;Qiao Jiang,&nbsp;Chunping Yang","doi":"10.1002/iid3.70217","DOIUrl":"https://doi.org/10.1002/iid3.70217","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>This study mainly explores the correlation between prognostic nutritional index (PNI) and systemic immune inflammatory index (SII) and sudden sensorineural hearing loss (SSNHL).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this study, 150 SSNHL patients (average age 48.98 ± 16.45 years; 48.92% male, 50.93% female) were categorized into effective and ineffective treatment groups. Additionally, 150 healthy volunteers (average age 49.49 ± 9.75 years; 51.08% male, 49.07% female) served as the control group. Baseline characteristics, clinical data, and laboratory results were collected, and SII and PNI were calculated for analysis. Linear correlation, logistic regression, and receiver characteristic curve analyses were conducted to explore the link between immune nutrition levels and SSNHL.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In the SSNHL group, PNI was significantly lower, while SII, platelet, and neutrophil counts were notably higher compared to controls (<i>p</i> &lt; 0.001). Logistic regression identified low PNI (OR = 0.878), high SII (OR = 1.005), and elevated neutrophils (OR = 1.758) as predictors of SSNHL. Data comparison showed higher nutritional levels in the effective treatment group than in the ineffective group. Logistic regression indicated that low PNI (OR = 1.075) and high SII (OR = 1.004) were strongly linked to treatment outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>There is a relationship between the body's immune nutrition level and the occurrence and development of SSNHL. Lower PNI and higher SII are associated with the occurrence of SSNHL and poor outcomes. However, further research into the underlying mechanisms is needed.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13289,"journal":{"name":"Immunity, Inflammation and Disease","volume":"13 6","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iid3.70217","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144300339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Arsenic Trioxide Enhances the Efficacy of PD-1 Inhibitors in Hepatocellular Carcinoma by Inducing Immunogenic Cell Death via the ROS/ERS Pathway","authors":"Xionghui Wang,&nbsp;Simo Cheng,&nbsp;Yannan Xu,&nbsp;Tianxiao Zheng,&nbsp;Changquan Ling,&nbsp;Juan Du","doi":"10.1002/iid3.70214","DOIUrl":"https://doi.org/10.1002/iid3.70214","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Hepatocellular carcinoma (HCC) remains a major global health challenge, with limited efficacy of current immunotherapeutic strategies. Immunogenic cell death (ICD), characterized by the release of damage-associated molecular patterns (DAMPs), offers a promising approach to enhance antitumor immunity. Arsenic trioxide (ATO), an ICD inducer, may synergize with PD-1 inhibitors to overcome therapeutic resistance, though the underlying mechanisms remain unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The cytotoxicity of ATO was evaluated via MTT, clonogenic, and apoptosis assays. ROS levels were quantified using ROS fluorescent probes. ERS activation was confirmed by Western blot detection of Calnexin, PDI, ATF-4, p-elF2α, and Caspase-12. ICD induction was assessed by measuring DAMPs (CRT exposure, HMGB1/ATP/IFN-β release). The roles of ROS/ERS pathways were dissected using NAC (ROS inhibitor) or 4-PBA (ERS inhibitor) pre-treatment. Ex vivo dendritic cell maturation assays analyzed ATO-treated HCC cells' immunostimulatory capacity, while In Vivo models evaluated immune microenvironment modulation via flow cytometry. Prophylactic/therapeutic tumor vaccine experiments assessed antitumor immunity using ATO-treated HCC cells as vaccines. Synergy between ATO and PD-1 blockade was tested in tumor-bearing mice by combining ATO with anti-PD-1 antibodies, monitoring tumor growth kinetics and survival outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>ATO dose-dependently reduced HCC cell viability while elevating intracellular ROS levels and activating ERS. These processes triggered the release/surface exposure of ICD-related DAMPs, including CRT, HMGB1, ATP, and IFN-β, leading to dendritic cells maturation and tumor immune microenvironment remodeling. ATO-treated HCC cells exhibited enhanced immunogenicity, functioning as prophylactic and therapeutic vaccines to stimulate antitumor immunity. Notably, ATO significantly potentiated the therapeutic efficacy of PD-1 inhibitors In Vivo.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>ATO induces ICD in HCC via a ROS/ERS signaling axis, thereby amplifying antitumor immune responses and synergizing with PD-1 blockade. These findings support the clinical evaluation of ATO-PD-1 inhibitor combinations to improve outcomes in HCC patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13289,"journal":{"name":"Immunity, Inflammation and Disease","volume":"13 6","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iid3.70214","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144264451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of Treatment and Subsequent Pregnancy Outcomes in Patients With Antinuclear Antibody-Positive Recurrent Spontaneous Abortion","authors":"Ancong Wang,&nbsp;Fengxia Wu,&nbsp;Min Liu,&nbsp;Zhenchun Zhang,&nbsp;Shuxia Li,&nbsp;Qihua Tan","doi":"10.1002/iid3.70216","DOIUrl":"https://doi.org/10.1002/iid3.70216","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The etiology of recurrent spontaneous abortion (RSA) has not been clearly defined. The role of autoantibodies in RSA has particularly attracted much attention.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>A retrospective analysis was performed to explore the combinatory efficacy of five drugs (aspirin enteric-coated tablets, hydroxychloroquine sulfate, methylprednisolone tablets, calcitriol capsules, and vitamin D calcium) in treating RSA patients with antinuclear antibody (ANA)-positive but could not be diagnosed with autoimmune diseases (AID) through assessment of treatment-related impact on subsequent pregnancy outcomes and adverse reactions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method of the Study</h3>\u0000 \u0000 <p>Patients who took medication regularly were defined as the observation group (125 cases), and patients who did not take medication or took medication less than 1 month as the control group (86 cases). According to the ANA titer, patients were further divided into subgroups of 1:100, 1:320, and 1:1000, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Comparison of the observation and the control groups without ANA subgrouping showed that the live birth rate in the observation group was higher (odds ratio 3.312, <i>p</i> &lt; 0.001), and the miscarriage rate was lower than that of the control group (odds ratio 0.302, <i>p</i> &lt; 0.001). Statistically significant results were obtained in ANA titer 1:100 subgrouping (<i>p</i> &lt; 0.001). There was no significant difference between the observation groups and the control groups for the ANA titers 1:320 and 1:1000. No statistically significant differences were observed in pregnancy rate, birthweight, neonatal 1-min Apgar score, and incidence of pregnancy complications between the observation and the control groups. Besides, the treatment showed a low incidence of adverse effects.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In summary, RSA patients who are ANA positive (titer 1:100) but not yet diagnosed as AID can have improved pregnancy outcomes after treatment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13289,"journal":{"name":"Immunity, Inflammation and Disease","volume":"13 6","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iid3.70216","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144264452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Visualization of Molluscum Contagiosum Virus in FFPE Skin Sections Using NanoSuit-CLEM: Ultrastructural Evidence of Viral Spread via Skin Barrier Disruption","authors":"Yuri Sakano,&nbsp;Hideya Kawasaki","doi":"10.1002/iid3.70212","DOIUrl":"https://doi.org/10.1002/iid3.70212","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Molluscum contagiosum (MC) is a common viral skin infection caused by members of the Poxviridae family. It primarily affects children, sexually active adults, and immunocompromised individuals. Although MC spreads through direct contact and auto-inoculation, the precise mechanisms by which the virus penetrates the skin barrier remain poorly understood.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We applied NanoSuit-correlative light and electron microscopy (NanoSuit-CLEM) to formalin-fixed paraffin-embedded (FFPE) skin sections to visualize MC virus particles in situ with high resolution. Melan-A immunohistochemistry using 3,3′-diaminobenzidine (DAB) with osmium staining was performed to identify Henderson–Patterson bodies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Ultrastructural analysis revealed that MC virus particles were densely localized in the stratum corneum but did not invade deeper epithelial layers in intact skin. However, in areas of epidermal disruption, such as detached or damaged stratum corneum, the virus was observed penetrating into lower layers. While Melan-A immunostaining successfully detected Henderson–Patterson bodies, it failed to identify mature MC virus particles. In contrast, NanoSuit-CLEM combined with Mayer's hematoxylin and lead staining enabled detailed visualization of mature viral particles and their distribution within the stratum corneum.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These findings provide direct ultrastructural evidence that MC virus entry occurs through compromised skin, underscoring the crucial role of the stratum corneum in barrier function. This study highlights the importance of preventing mechanical skin injury, such as scratching or shaving, to limit MC transmission. NanoSuit-CLEM offers a powerful new tool for studying viral pathogenesis in archival tissue samples.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13289,"journal":{"name":"Immunity, Inflammation and Disease","volume":"13 6","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iid3.70212","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144197492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RETRACTION: lncRNA BZRAP1-AS1 Alleviates Rheumatoid Arthritis by Regulating miR-1286/COL5A2 Axis","authors":"","doi":"10.1002/iid3.70204","DOIUrl":"https://doi.org/10.1002/iid3.70204","url":null,"abstract":"<p><b>RETRACTION:</b> J. Zhu, S. Tu and Q. Qu, “lncRNA BZRAP1-AS1 Alleviates Rheumatoid Arthritis by Regulating miR-1286/COL5A2 Axis,” <i>Immunity, Inflammation and Disease</i> 10, no. 2 (2022): 163-174, https://doi.org/10.1002/iid3.558.</p><p>The above article, published online on 11 November 2021 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Marc Veldhoen; and John Wiley &amp; Sons, Ltd. The retraction has been agreed upon due to inconsistencies and flaws identified in this article that affect the validity of the conclusions. The authors did not respond to address the concerns raised and did not provide their original data. The editors consider the results and conclusions reported in this article unreliable. The authors were informed of the retraction.</p>","PeriodicalId":13289,"journal":{"name":"Immunity, Inflammation and Disease","volume":"13 5","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iid3.70204","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144148460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RETRACTION: NEAT1 Enhances MPP + -Induced Pyroptosis in a Cell Model of Parkinson's Disease via Targeting miR-5047/YAF2 Signaling","authors":"","doi":"10.1002/iid3.70208","DOIUrl":"https://doi.org/10.1002/iid3.70208","url":null,"abstract":"<p><b>RETRACTION:</b> H. Shen, H. Song, S. Wang, D. Su and Q. Sun, “NEAT1 Enhances MPP + -Induced Pyroptosis in a Cell Model of Parkinson's Disease via Targeting miR-5047/YAF2 Signaling,” <i>Immunity, Inflammation and Disease</i> 11, no. 6 (2023): e817, https://doi.org/10.1002/iid3.817.</p><p>The above article, published online on 23 June 2023 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Marc Veldhoen; and John Wiley &amp; Sons, Ltd. The retraction has been agreed upon due to the ASC western blot bands in Figure 1 C being found duplicated in a previously published article, representing a different scientific context. The authors were contacted for comment and supporting data but did not respond. The editors consider the results and conclusions of this article unreliable. The authors were informed of the retraction.</p>","PeriodicalId":13289,"journal":{"name":"Immunity, Inflammation and Disease","volume":"13 5","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iid3.70208","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144148461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of P2X7R in Retinal Diseases: A Review","authors":"Chunli Li,&nbsp;Binsheng Wang","doi":"10.1002/iid3.70203","DOIUrl":"https://doi.org/10.1002/iid3.70203","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>P2X purinoceptor 7 receptor (P2X7R) is an ATP-gated ion channel that, upon activation by ATP, triggers the release of inflammatory mediators and induces apoptosis in cells. This channel plays a crucial role in the onset and progression of various diseases. Recently, there has been a growing body of research focused on the function of P2X7R receptors in ophthalmic conditions, particularly concerning retinal diseases such as age-related macular degeneration, diabetic retinopathy, and retinitis pigmentosa.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This article is to provide a comprehensive review of the advancements in the study of P2X7R and its association with retinal diseases, elucidating its role in these conditions and identifying potential avenues for future research.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Electronic databases, including PubMed, Web of Science, and Wan fang Data were searched for relevant literature. The following keywords were used: “P2X7R”, Age-related macular degeneration”, “Diabetic retinopathy”, “Retinitis pigmentosa”. Both preclinical and clinical studies were included to provide a holistic understanding of P2X7R's role in retinal pathology.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>P2X7R activation exacerbates retinal diseases by promoting inflammation and apoptosis. However, its role in disease progression and homeostasis complicates therapeutic targeting, highlighting the need for selective inhibitors and further research into its context-dependent functions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>P2X7R plays a critical role in the pathogenesis of retinal diseases. At the same time, preclinical studies suggest that P2X7R inhibition holds promise as a therapeutic strategy. Future research should focus on developing selective P2X7R inhibitors, elucidating the receptor's role in different disease stages, and identifying biomarkers to guide personalized treatment. Addressing these challenges will be essential for translating P2X7R-targeted therapies into clinical practice and improving outcomes for patients with retinal diseases.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13289,"journal":{"name":"Immunity, Inflammation and Disease","volume":"13 5","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iid3.70203","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144100808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}